Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab /carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide (AC) for newly diagnosed primary triple-negative inflammatory breast cancer (TNIBC)
Year: 2018
Type: conference-abstract
Source: Cancer Research
Authors: JS Willey, CA Parker, B Lim, V Valero, HT Le-Petross, S Krishnamurthy, WA Woodward, A Lucci, AL Wood, H Sun, GV Babiera, J Song, Y Shen, V Valero, X Wang, NT Ueno
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2789262105